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Acceptability and Feasibility of a Pharmacist-Led Human 
Immunode"ciency Virus Pre-Exposure Prophylaxis 
Program in the Midwestern United States
Joshua P. Havens,1,3 Kimberly K. Scarsi,3 Harlan Sayles,2 Donald G. Klepser,3 Susan Swindells,1 and Sara H. Bares1
1Division of Infectious Diseases, 2Department of Biostatistics, and 3Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha
Background. Human immunode"ciency virus (HIV) pre-exposure prophylaxis (PrEP) substantially reduces the risk of HIV 
acquisition, yet signi"cant barriers exist to its prescription and use. Incorporating pharmacists in the PrEP care process may help 
increase access to PrEP services.
Methods. Our pharmacist-led PrEP program (P-PrEP) included pharmacists from a university-based HIV clinic, a community 
pharmacy, and 2 community-based clinics. $rough a collaborative practice agreement, pharmacists conducted PrEP visits with po-
tential candidates for PrEP, according to the recommended Centers for Disease Control and Prevention guidelines, and authorized 
emtricitabine-tenofovir disoproxil fumarate prescriptions. Demographics and retention in care over 12 months were summarized, 
and participant satisfaction and pharmacist acceptability with the P-PrEP program were assessed by Likert-scale questionnaires.
Results. Sixty patients enrolled in the P-PrEP program between January and June 2017 completing 139 visits. $e mean age was 
34 years (range, 20–61 years), and 88% identi"ed as men who have sex with men, 91.7% were men, 83.3% were white, 80% were 
commercially insured, and 89.8% had completed some college education or higher. Participant retention at 3, 6, 9, and 12 months 
was 73%, 58%, 43%, and 28%, respectively. To date, no participant has seroconverted. One hundred percent of the participants who 
completed the patient satisfaction questionnaire would recommend the P-PrEP program. Pharmacists reported feeling comfortable 
performing point-of-care testing and rarely reported feeling uncomfortable during PrEP visits (3 occasions, 2.2%) or experiencing 
work&ow disruption (1 occasion, 0.7%).
Conclusions. Implementation of a pharmacist-led PrEP program is feasible and associated with high rates of patient satisfaction 
and pharmacist acceptability.
Keywords. HIV pre-exposure prophylaxis; HIV prevention; pharmacist-led.
Preventing human immunodeficiency virus (HIV) acquisition 
remains a challenge more than 3 decades after the discovery of 
the virus. Currently available biomedical HIV prevention ap-
proaches include the diagnosis and treatment of HIV, daily oral 
HIV pre-exposure prophylaxis (PrEP), and HIV postexposure 
prophylaxis. When taken once daily, emtricitabine/tenofovir 
disoproxil fumarate (F/TDF) is safe and highly effective in the 
prevention of HIV acquisition, but its utilization is limited for 
many reasons including lack of patient and provider knowledge 
and awareness, treatment access, and stigma [1–3].
$ere has been much debate about the optimal setting 
in which to provide PrEP. Human immunode"ciency virus 
practitioners believe primary care physicians (PCP) are best 
suited to prescribe PrEP because of their access to HIV-
uninfected populations [4]. Although e'orts are being made to 
educate PCP’s about PrEP, PCP’s are o+en uncomfortable with 
PrEP management [5–7]. Furthermore, in a survey of men who 
have sex with men (MSM), 80% stated that they did not want to 
talk to their PCP about PrEP [8].
Many areas of the Midwestern United States are designated 
as federal medically underserved areas, demonstrating re-
duced access to primary care services in general and partic-
ularly for specialty healthcare services in rural areas. Persons 
at risk for HIV acquisition may have di:culty accessing pre-
ventive services despite actively seeking PrEP. Furthermore, 
1 in 8 PrEP-eligible patients would require greater than 30 
minutes of travel to visit a PrEP provider in most rural areas 
[9]. Implementation of home-based and telehealth PrEP have 
demonstrated some acceptability and feasibility as an alterna-
tive to medical clinic-based PrEP [10–13]. With over 60 000 
community pharmacies in the United States, representing 13 
billion pharmacy visits annually, the community pharmacy 
potentially o'ers an alternative setting to reach individuals at 
risk for HIV acquisition [14].
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Prior studies have demonstrated successful collaboration of 
pharmacists with other healthcare providers and health depart-
ments in HIV prevention e'orts through programs ranging 
from HIV screening to pharmacy-based syringe distribution 
and postexposure prophylaxis services [15–18]. Individual 
states regulate pharmacists’ patient care services through 
scope-of-practice laws and related rules. Depending on state 
laws, pharmacists may provide an array of patient care serv-
ices through collaborative practice agreements (CPA) with 
medical providers. Collaborative practice agreements create a 
formal relationship between a pharmacist and a prescriber and 
allow the prescriber to delegate speci"ed patient care respon-
sibilities to the pharmacist under negotiated conditions within 
the agreement. Nebraska state law explicitly authorizes CPA, 
allowing pharmacists to facilitate and manage a variety of pa-
tient care services including point-of-care testing (POCT) and 
treatment for bacterial and viral respiratory illnesses, such as 
streptococcal pharyngitis and in&uenza [19, 20]. Building on 
these models, a collaborative drug therapy management plan 
would allow pharmacists working within the context of a de-
"ned HIV PrEP protocol to assume professional responsibility 
for all aspects of PrEP administration, including performing 
patient assessments, ordering and interpreting laboratory tests, 
performing POCT, patient counseling, and dispensing and 
monitoring PrEP treatment [21].
Clinical pharmacists have been incorporated into PrEP de-
livery models in Miami, Florida, and Seattle, Washington [22, 
23]. $e Miami Veterans A'airs Health System model utilized 
pharmacists to optimize adherence and retention in care in be-
tween the scheduled quarterly visits but did not incorporate in-
dependent pharmacist visits at the quarterly clinical visits. Tung 
and colleagues have described a robust pharmacist-led PrEP de-
livery program, but they are unique in their ability to perform 
phlebotomy and other procedures outside the scope of tradi-
tional community pharmacies.
$is pilot study investigated the acceptability and feasibility 
of a pharmacist-led HIV screening and PrEP program (P-PrEP) 
for individuals at risk for HIV acquisition in Omaha, Nebraska, 
including the number of patients initiated on PrEP, retention 
in PrEP care, and patient and pharmacist satisfaction with the 
program.
METHODS
Patient Participants
Participants were recruited in the P-PrEP program through self-
referral or referral by friends or partners, their PCP, local HIV/
acquired immune deficiency syndrome (AIDS) service organi-
zations, county sexually transmitted infection (STI) clinics, or 
local HIV clinics. Eligibility for P-PrEP inclusion was as follows: 
(1) HIV-uninfected patients aged greater than 19 years of age 
(the age of majority in Nebraska); (2) at high-risk of acquiring 
HIV (naive or PrEP-experienced) based on 1 or more of the 
following risk factors—(a) MSM who engage in condomless 
anal intercourse, (b) individuals who are in a serodiscordant 
sexual relationship with a known HIV-positive partner, (c) 
transgender individuals who engage in condomless intercourse, 
(d) individuals engaging in transactional sex, (e) injection drug 
users, (e) individuals who use stimulant drugs associated with 
high-risk behaviors, such as methamphetamine, (f) individuals 
diagnosed (self-reported or by recent STI testing) with at least 
1 anogenital STI in the last year, (g) individuals who have ever 
been prescribed nonoccupational postexposure prophylaxis 
(nPEP) demonstrating continued high-risk behavior or have 
used 2 or more courses of nPEP—(3) English-speaking; (4) 
serum creatinine less than 1.5 times the upper limit of normal; 
(5) nonreactive hepatitis B surface antigen; and (6) no signs 
or symptoms of acute HIV infection within the past 30 days. 
This study was approved by the University of Nebraska Medical 
Center Investigational Review Board, and all participants pro-
vided written informed consent.
Participating Pharmacists
Pharmacists at a university-based HIV clinic, a community 
pharmacy, a university-based primary care clinic, and a 
Federally Qualified Health Center primary care clinic were re-
cruited as P-PrEP pharmacist providers based on proximity and 
access to high-risk populations, willingness to participate, and 
acceptance by their leadership management team.
Intervention
Pharmacist-led PrEP was designed as a pharmacist-led program 
allowing participating pharmacists to serve as PrEP providers 
through the utilization of a CPA. A  CPA specifying pharma-
cist responsibilities within the P-PrEP program was completed 
between the university-based HIV medical providers and each 
participating P-PrEP pharmacist. Each participating P-PrEP 
pharmacist completed the National Association of Chain Drug 
Stores Point-of-Care certificate program [24]. The P-PrEP 
pharmacists were provided additional education on HIV risk 
assessment, testing, risk reduction counseling, and administra-
tion of PrEP from faculty of the Nebraska AIDS Education and 
Training Center located at the University of Nebraska Medical 
Center. Upon completion of training, P-PrEP pharmacists as-
sumed responsibility for the PrEP care of individuals enrolled 
in P-PrEP through the CPA.
$e screening and initial visit was conducted by the P-PrEP 
pharmacist at the university-based HIV clinic site to ensure 
complete collection of all baseline laboratory tests and con-
senting procedures. $e university-based HIV clinic pharmacist 
collected basic demographic and socioeconomic information, 
completed a medical history, an HIV risk assessment based on 
the study eligibility criteria through conduction of sexual, STI 
(self-reported chlamydia, gonorrhea, and syphilis infections), 
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and substance use histories, PrEP counseling, baseline labora-
tory testing, and performed HIV and STI screening. If clinical 
information such as laboratory testing, STI testing, etc per-
formed at another healthcare facility was needed, the partici-
pant signed a Health Insurance Portability and Accountability 
Act of 1996 release form to gain access to such data. Eligible 
P-PrEP participants were provided a 90-day F/TDF prescrip-
tion. Each participant was given the option to continue PrEP 
care at the university-based HIV clinic or at 1 of the other 3 
participating sites (community pharmacy, university-based pri-
mary care clinic, or Federally Quali"ed Health Center primary 
care clinic). Primary care services were integrated with PrEP 
at the university-based and Federally Quali"ed Health Center 
primary care clinics through a patient-centered medical home 
model. All participants were encouraged to engage in care with 
a PCP if no current PCP relationship was in place.
Pharmacist-led PrEP participants presented for follow-up 
visits every 3  months a+er PrEP initiation, and laboratory 
monitoring was performed according to Centers for Disease 
Control and Prevention HIV PrEP guidelines [25]. Follow-up 
visits completed at a clinic-based site (university-based HIV 
clinic, university-based primary care clinic, and Federally 
Quali"ed Health Center primary care clinic) were conducted 
in clinic exam rooms, and all charting and laboratory test col-
lections were performed by each clinic’s standard procedures. 
Follow-up visits conducted at the community pharmacy site oc-
curred in a private room, and all POCT was performed at the 
community pharmacy and interpreted by the pharmacist.
At all follow-up sites, a sample of whole blood by "nger stick 
was collected for HIV screening using a fourth-generation 
HIV 1/2 Antibody/Antigen test (Alere Determine; Abbott 
Laboratories, Chicago, IL), and urine, rectal, and pharyn-
geal specimens were obtained for Chlamydia trachomatis and 
Neisseria gonorrheae by deoxyribonucleic acid probe assay 
(Aptima Combo 2; Hologic, Marlborough, MA). Sexually 
transmitted infection screenings for chlamydia and gonorrhea 
at the community pharmacy site were self-collected by the par-
ticipant. Participants provided urine specimens and were edu-
cated on self-collection of pharyngeal and rectal specimens for 
STI screening. Chlamydia and gonorrhea STI specimens were 
collected by the pharmacy for delivery by courier to a local 
hospital-based laboratory for processing with the results re-
ported to university-based HIV clinic clinical sta' for interpre-
tation and coordination of STI treatment if applicable.
At the community pharmacy site, whole blood by "nger stick 
was collected for rapid analysis of blood creatinine (i-STAT 
Handheld Analyzer; Abbott Laboratories, Chicago, IL) and 
Treponema palladium antibody screening (Syphilis Health 
Check; Diagnostics Direct, LLC, Stone Harbor, NJ). All safety 
blood tests conducted at the clinic-based sites (university-based 
HIV clinic, university-based primary care clinic, and Federally 
Quali"ed Health Center primary care clinic), including syphilis 
screening (BioPlex 2200 Syphilis Total and RPR Kit; Bio-Rad, 
Hercules, CA), were collected by venipuncture in compliance 
with standard practices for follow-up visits. If appropriate, 
the pharmacist initiated a new 3-month F/TDF prescription 
as designated through the CPA bylaws. Follow-up visits were 
scheduled for all clinic-based sites but not for the community 
pharmacy site. Instead, the participant was able to walk-in to 
the community pharmacy at their convenience for the next 
quarterly P-PrEP visit.
Study Assessments
The primary outcome measure was the total number of par-
ticipants initiated on F/TDF for PrEP. Secondary outcome 
measures included the following: (1) adherence to F/TDF, (2) 
number of patients retained at 3, 6, 9, and 12 months, (3) patient 
satisfaction with P-PrEP services, and (4) pharmacist satisfac-
tion with P-PrEP services.
Assessment of adherence to F/TDF while engaged in the 
P-PrEP program occurred at each follow-up visit for the pre-
ceding 3 months by calculation of a medication possession ratio 
(total number of F/TDF doses dispensed/total number of days 
between study follow-up visits) [26]. Retention in PrEP care 
within the P-PrEP program was determined as the total number 
of patients completing follow-up visits at 3, 6, 9, and 12 months.
Protocol-derived questionnaires, designed with Likert-scale 
and open-ended questions, to assess participant satisfaction 
and pharmacist experience of the P-PrEP program were com-
pleted by participants retained at the 6-month visit and at each 
visit for the pharmacists. $e respondents completed ques-
tionnaires independently, and identifying information was not 
included on the questionnaires. Participants were asked to de-
scribe their P-PrEP experience regarding the quality of PrEP 
education provided, interactions with pharmacists, privacy, col-
lection of laboratory specimens, timeliness of follow-up visits, 
ease of medication access, and maximal amount participants 
would pay for P-PrEP if o'ered (community pharmacy site 
only). Pharmacists were asked to describe their comfort level 
with conducting P-PrEP visits and performing POCT. Time re-
quirements for performing POCT, PrEP consultation, and visit 
entirety were recorded.
Descriptive statistics were used to summarize all study data 
including the participant demographics, baseline characteris-
tics, and participant/pharmacist P-PrEP satisfaction. Survival 
analysis via Kaplan-Meier estimators and log-rank tests were 
used to evaluate demographic characteristics associated with 
retention in PrEP care.
RESULTS
Participant Characteristics
From January 1, 2017 through June 30, 2017, 60 participants 
enrolled in the P-PrEP program and started F/TDF. The ma-
jority, 91.7% (55 of 60), were men, 83.3% (50 of 60) were white, 
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80% (48 of 60)  were commercially insured, and 89.8% (54 of 
60)  had completed some college or higher. The mean age of 
participants was 34 years (range, 20–61 years), and 88.3% (53 
of 60)  identified as MSM. The mean creatinine clearance was 
130  mL/minute (range, 89–172  mL/minute). Fourteen parti-
cipants (23%) were diagnosed with chlamydia or gonorrhea at 
the baseline visit for a total number of 22 diagnosed infections. 
Rectal and pharyngeal infections were most common at base-
line (4 rectal gonorrhea, 9 rectal chlamydia, and 6 pharyngeal 
gonorrhea). No incident syphilis infections were diagnosed at 
baseline; however, 10 participants (17%) had a previous history 
of syphilis infection and treatment (Table 1).
Retention and Adherence
Almost all of the participants (55 of 60; 91.7%) chose either 
the university-based HIV clinic or community pharmacy as 
their preferred follow-up site (university-based HIV clinic, 28, 
46.7%; community pharmacy, 27, 45%). A total of 139 P-PrEP 
follow-up visits occurred over the course of the study period 
totaling 30.75 person years of follow-up. There were zero HIV 
seroconversions.
Retention within the P-PrEP program fell throughout the du-
ration of the study with 73%, 58%, 43%, and 28% of the partici-
pants retained at 3, 6, 9, and 12 months, respectively. Participant 
retention per site is described in Figure 1. Participants without 
private insurance and those who were not MSM engaging in 
unprotected anal intercourse dropped out signi"cantly sooner 
than other participants (log-rank test P = .033 and P = .001, re-
spectively). Among participants retained throughout the study, 
adherence to F/TDF remained high with a mean medication 
possession ratio of 93%.
Sexually Transmitted Infections
A total of 29 STIs (11 chlamydia, 17 gonorrhea, 1 syphilis) were 
diagnosed throughout the study demonstrating 0.94 incident 
STI infections per person years of follow-up. The majority were 
observed at the baseline visit upon P-PrEP enrollment. Overall 
STI prevalence decreased over the course of the study (data not 
shown).
Participant Satisfaction
Of the 35 participants completing the 6-month visit, a total of 29 
participants completed the P-PrEP satisfaction questionnaire: 
13 (44.8%) from the community pharmacy site, 16 (55.2%) from 
the university-based HIV clinic site, and none from either the 
university-based primary care clinic or the Federally Qualified 
Health Center primary care clinic sites. All of the respondents 
stated they would definitely recommend the P-PrEP program. 
Respondents reported the P-PrEP program allowed for ease of 
PrEP care, quick service, extended hours for follow-up visits, 
and friendly and honest pharmacists. The ease of medication 
access, confusion with the collection of rectal and pharyngeal 
STI swabs, and delayed communication between pharmacist 
providers and medical providers were noted as areas needing 
improvement for the P-PrEP program (Figure 2). Of the par-
ticipants who completed follow-up visits at the community 
Table 1. Baseline Characteristics of Participants
Baseline Characteristic All Participants, n = 60
Age (years), mean (range) 34 (20–61)
Gender, n (%)  
 Male 55 (91.7)
 Female 3 (5.0)
 Transgender male 2 (3.3)
 Transgender female 0 (0)
Race and Ethnicity, n (%)a  
 White 50 (83.3)
 Latinx 5 (8.3)
 African American 5 (8.3)
 Asian or Pacific Islander 2 (3.3)
 Other 1 (1.7)
Insurance Coverage, n (%)  
 Private/Commercial 48 (80.0)
 Medicare 1 (1.7)
 Medicaid 0 (0)
 Uninsured 11 (18.3)
Education Completed, n (%)  
 Less than high school diploma or GED 0 (0)
 High school diploma or GED 6 (10.2)
 Some college, no degree 19 (32.2)
 Two-Year Associates Degree 3 (5.1)
 Bachelor Degree 17 (28.8)
 Some Postgraduate education 2 (3.4)
 Postgraduate or professional degree 12 (20.3)
HIV Risk Factor, n (%)b  
 MSM-UAI 53 (88.3)
 Sexually active with HIV+ partner 17 (28.3)
 Transgender person engaging in high-risk behavior 2 (3.3)
 Transactional sex 1 (1.7)
 Injection drug use 0 (0)
 Use of stimulant (eg, methamphetamine, MDMA) 1 (1.7)
 Anogenital STI within 1 year 19 (31.7)
 Previous nPEP prescription 3 (5.0)
Any Baseline Sexually Transmitted Infection, n (%)c 14 (23)
 Chlamydia  
  Anal 9 (15.0)
  Pharyngeal 0 (0)
  Urogenital 1 (1.7)
 Gonorrhea  
  Anal 4 (6.7)
  Pharyngeal 6 (10.0)
  Urogenital 2 (3.3)
 Syphilis  
  New diagnosis 0 (0)
  History of infection 10 (17.0)
Abbreviations: GED, General Education Diploma; HIV, human immunodeficiency virus; 
MDMA, 3,4-methylenedioxymethamphetamine, “Ecstasy”; MSM-UAI, men who have sex 
with men-unprotected anal intercourse; nPEP, nonhealthcare HIV postexposure prophy-
laxis; STI, sexually transmitted infections.
NOTE: Except where indicated, data are presented as n (%) of study group participants.
aSome participants reported multiple categories leading to unequal total proportion.
bSome participants reported multiple categories leading to unequal total proportion.
cSome participants reported multiple categories leading to unequal total proportion.
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Pharmacist-led HIV PrEP Program • OFID • 5
pharmacy, half (6 of 12) stated they would be willing to pay at 
least $20 quarterly for continued PrEP visits with the remaining 
participants willing to pay up to $60 quarterly. One participant 
at the community pharmacy site did not respond to the cost 
consideration question.
Pharmacist Satisfaction
A total of 7 pharmacists (1 university-based HIV clinic, 3 com-
munity pharmacy, 1 university-based primary care clinic, and 
2 Federally Qualified Health Center primary care clinic) par-
ticipated in P-PrEP. The P-PrEP pharmacists felt comfortable 
performing POCT at all visits except on 1 occasion (0.7%). 
Furthermore, 1 pharmacist at the community pharmacy site 
reported 3 occasions (2.2%) in which they felt uncomfortable 
conducting sexual histories during P-PrEP follow-up visits. 
Workflow disruption at the community pharmacy site was 
reported only once (0.7%) throughout the study. The mean 
reported times for performing POCT, PrEP counseling, and 
total visit times were 8.7, 16, and 28 minutes, respectively 
(Figure 3).
DISCUSSION
In this pilot investigation of a P-PrEP, we successfully initiated 
PrEP in 60 participants at risk for HIV acquisition and found a 
high overall acceptance rate by both the participants and phar-
macists. These data support P-PrEP as a desirable and feasible 
option for PrEP delivery and scale-up.
Baseline
University-based HIV
Clinic
N
u
m
b
er
 o
f 
P
a
rt
ic
ip
a
n
ts
Community Pharmacy University-based Primary
Care Clinic
Follow-up Site
Community-Based
Primary Care Clinic
30 28
21
17
13
9
27
21
18
12
8
4
2
1 1
0
1
0 0 0 0
25
20
15
10
5
0
3 Months 6 Months 9 Months 12 Months
Figure 1. Pharmacist-led pre-exposure prophylaxis program participant totals through study duration notated separately by follow-up site. All baseline visits were con-
ducted at the university-based human immunodeficiency virus (HIV) clinic site. The participant totals for the baseline visit is representative of the participant’s choice of 
follow-up site after study entry.
The timeliness your lab results were communicated back to you
The ease of  accessing your medication
The way STI screenings were collected
The way your blood tests were collected
The way your pharmacists worked with the prescribing physician
Privacy of  your conversation with the pharmacist
Information the pharmacist provided regarding medication side eects
Pharmacist interest in your health
Very Satisfied Satisfied Neither Satisfied or Dissatisfied Dissatisfied
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Very Dissatisfied
Figure 2. Participant satisfaction with the pharmacist-led pre-exposure prophylaxis program. STI, sexually transmitted infection. 
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Retention in care decreased over the course of the study, 
with just over half retained at 6 months and approximately one 
quarter retained at 12 months. Although disappointing, these 
retention rates are similar to retention rates seen in other real-
world PrEP implementation studies [27–29]. Furthermore, 
we identi"ed similar drivers of poor retention that included 
both structural (insurance coverage) and individual (HIV risk 
factor) factors. More important, a high rate of medication ad-
herence was seen in retained participants. $e e'ectiveness of 
PrEP ultimately depends on adherence to the prescribed med-
ication, so the high rates of adherence among those retained in 
care are encouraging.
$e P-PrEP follow-up visits performed at the community 
pharmacy were quick and convenient for participants. $e 
adoption of a P-PrEP may allow for increased PrEP access in 
rural settings by reducing travel times and potentially o'ering 
a lower cost option for PrEP follow-up, which is an important 
consideration in light of the Trump administration’s plan to 
end the HIV epidemic [30]. Furthermore, the pharmacy may 
be an acceptable setting for future PrEP formulations, such as 
intramuscular cabotegravir, considering pharmacists’ current 
integration into other long-acting medical treatments and vac-
cination administration [31–34].
$e community pharmacy site used in this pilot study was a 
small, independent pharmacy with signi"cant buy-in by its phar-
macists and pharmacist owner. Pharmacy work&ow disruption 
and leadership acceptance should be considered as potential 
barriers to implementation of P-PrEPs at other sites as evident 
from a recent survey of Midwest pharmacists in which concerns 
of work&ow disruption and acceptance by leadership were cited 
as a concern, in spite of high pharmacist interest in provision 
of PrEP services [35]. In addition, the balance of cost to the pa-
tient and compensation to the pharmacy should be considered 
for program sustainability. Challenges remain in pharmacist 
compensation for these services because not all states allow 
pharmacists to bill for professional services [15]. $e One-Step 
PrEP program, another P-PrEP in Seattle, Washington, was "-
nancially sustainable, but pharmacists are permitted to legally 
bill Medicaid for services provided in the state, allowing this 
model to be implemented more easily in Washington in com-
parison to states without this provision [13]. $e P-PrEP parti-
cipants at the community pharmacy in our study received PrEP 
care, POCT, and STI screening free of charge. All participants 
receiving care at a clinic-based P-PrEP site were not charged for 
the PrEP visit, but all laboratory and STI screenings were billed 
by standard procedures. Participants at the community phar-
macy were willing to pay from $20 to $60 quarterly, amounting 
to approximately the cost of the POCT supplies and allowing 
for little compensation for the pharmacist’s time and e'ort for 
PrEP services. However, additional pharmacy revenue through 
F/TDF prescription reimbursements could potentially subsi-
dize some of those costs.
Laboratory management and STI screening was a logistical 
challenge at the community pharmacy site. No CLIA-waived 
POC test is currently available to distinguish between previous 
and incident syphilis infections nor for hepatitis B screening, 
and, thus, both require venipuncture and subsequent processing 
at a clinical laboratory. $e PrEP@Home study used the rapid 
plasma reagin card for syphilis screening (Arlington Scienti"c, 
Inc, Springville, UT), eliminating the need for venipuncture, al-
though it still requires processing at a clinical laboratory [7]. 
$e collection and couriered delivery of STI specimens and 
0%
Strongly Disagree Disagree Neither Agree or Disagree Agree Strongly Agree Not Applicable
Visit disrupted my work flow
Comfortable performing Point of  Care Testing
Comfortable counseling the patient
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Figure 3. Pharmacist assessment of workflow disruption and comfortability with point-of-care testing and pre-exposure prophylaxis (PrEP) counseling, per pharmacist-led 
PrEP visit.
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subsequent communication of results back to patients and 
providers are challenging to execute from a community phar-
macy setting. Given these laboratory considerations, initial pre-
scription of PrEP in the community pharmacy setting is likely 
not practical. However, P-PrEP care in the community phar-
macy setting may be well suited for PrEP follow-up and poten-
tially for HIV screening and linkage to care and postexposure 
prophylaxis.
$ere were some limitations to our study. $e P-PrEP was a 
pilot study and thus included a small number of participants. 
Larger scale studies may help further determine the reproduc-
ibility of this model of PrEP delivery in various regions. Key 
patient populations were not well represented within our study 
population, including women, transgender persons, minority 
populations, and non-English-speaking patients. Research to 
help engage and retain these high-risk populations should con-
tinue to be explored. Finally, patient satisfaction may have been 
skewed towards the positive given that questionnaires were col-
lected only from those who remained engaged in PrEP care at 
the 6-month visit at which time retention had dropped o'.
CONCLUSIONS
Implementation of a P-PrEP is feasible with high rates of pa-
tient satisfaction and pharmacist acceptability. Its utilization 
may be of speci"c bene"t to patients living in underserved or 
rural areas to increase PrEP access and allow for patient con-
venience. Despite concerns of patient cost, pharmacist compen-
sation and work&ow disruption, and the logistical challenges of 
laboratory and STI screening, the community pharmacy should 
remain a potential option for PrEP follow-up.
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